Qiagen is a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. Consolidated under the Dutch holding Qiagen N.V., the company operates more than 35 offices in over 25 countries. Qiagen’s shares are listed at the technology-focused U.S. stock exchange Nasdaq (using ticker QGEN) and at the Frankfurt Stock Exchange in the Prime Standard (using ticker QIA). Peer M. Schatz is the company’s Chief Executive Officer. The main operative headquarters are located in Hilden, Germany (near Düsseldorf). QIAGEN is a worldwide provider of molecular sample and assay technologies. Sample technologies are used to collect samples of tissue, fluids, etc. and stabilize, extract and purify various molecules of interest such as DNA, RNA or proteins from other cellular components. Assay technologies are then used to amplify (multiply) and enrich this small amount of isolated material to make it visible, readable and ready for interpretation. The separation and purification of genetic information is a basic precondition for further application or analysis. Qiagen provides molecular technologies offered as kits with open or specific target analytes. According to Qiagen, the company’s current portfolio covers more than 500 products and more than 2,000 patents and licenses.
Highest paying job titles at Qiagen include Regulatory Affairs Manager, Business Development Director, and Sales Representative